As Korean CDMO giant Samsung Biologics continues to ink production pacts around the globe, the company has added another billion-dollar feather to its cap.
Fierce Pharma
Internet News
New York, New York 89,893 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Biogen’s Leqembi—a full approval.
Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod
fiercepharma.com
-
In a new USA Today op-ed piece, President Joe Biden and Sen. Bernie Sanders blasted Novo Nordisk for "charging the American people unconscionably high prices" for its popular GLP-1 medicines Ozempic and Wegovy.
Biden joins Sanders' campaign targeting Novo Nordisk, Eli Lilly's diabetes and obesity drug prices
fiercepharma.com
-
For its latest celebrity partnership, Pfizer went in a “Fabulous” direction.
Pfizer bops to the top with new Ashley Tisdale collab around alopecia areata
fiercepharma.com
-
Noncompete agreements have threatened executive moves in biopharma in the past. Will that block Giovanni Caforio's plans?
As former BMS CEO Giovanni Caforio plots move to Novartis, will noncompete issues come into play?
fiercepharma.com
-
Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said.
FDA commissioner heralds end to US shortfall of chemo drug cisplatin
fiercepharma.com
-
Seventeen months after SK Bioscience introduced its global expansion push—memorably dubbed as “SKBS 3.0”—the Korean developer and manufacturer of vaccines has pulled off a deal that lives up to its ambitions.
SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika
fiercepharma.com
-
The RSV vaccine showdown already saw a shake-up last month with a new competitor in Moderna’s mRESVIA. Now, all three vaccine offerings face a potentially shrunken market.
CDC immunization advisers vote to shrink recommendations for RSV vaccination
fiercepharma.com
-
the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan.
Daiichi's lung cancer ADC rejected by FDA in blow to first project under Merck partnership
fiercepharma.com
-
It finally appears to be go-time in Sanofi’s continuing effort to separate from its consumer health unit.
Sanofi asks for private equity bids for its consumer health unit: Bloomberg
fiercepharma.com